| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥129.4B | ¥117.7B | +9.9% |
| Operating Income | ¥16.0B | ¥20.1B | -20.5% |
| Ordinary Income | ¥15.8B | ¥19.1B | -17.4% |
| Net Income | ¥10.8B | ¥13.5B | -19.7% |
| ROE | 2.9% | 3.7% | - |
FY2025 Q1 results: Revenue 129.4B yen (YoY +9.9%), Operating Income 16.0B yen (YoY -20.5%), Ordinary Income 15.8B yen (YoY -17.4%), Net Income 10.8B yen (YoY -19.7%). The company demonstrated revenue expansion driven by growth across both business segments, while profitability declined substantially due to increased SG&A expenses and interest costs. Operating margin contracted to 12.3% from the prior period, reflecting cost pressures that outpaced top-line growth. The revenue-up/profit-down pattern indicates structural cost challenges requiring operational efficiency improvements.
Revenue increased 11.7B yen to 129.4B yen, representing +9.9% YoY growth. The Ishinkan segment contributed 127.4B yen in revenue with +9.2% growth, while the Comprehensive Medical Support segment recorded 2.0B yen, more than doubling from the prior period's 1.0B yen (implied from segment notes). Gross profit margin held steady at 28.7%, with gross profit of 37.1B yen advancing proportionally with revenue. The primary revenue drivers were expansion of existing facilities and increased utilization rates in the core medical support services business.
Operating income decreased 4.1B yen to 16.0B yen despite revenue growth. SG&A expenses rose to 21.1B yen (16.3% of revenue) from 17.0B yen in the prior period, an increase of 24.1% that significantly exceeded revenue growth. The Ishinkan segment operating profit declined to 16.1B yen from 20.0B yen (implied from prior segment profit), with margin compression from 17.1% to 12.6%. The Comprehensive Medical Support segment posted a loss of 0.1B yen with a negative margin of -5.0%. Operating margin deterioration of 4.8 percentage points reflects operational deleverage and startup costs in the expansion phase.
Ordinary income of 15.8B yen declined 17.4% YoY, closely tracking operating income trends. Non-operating expenses totaled 1.6B yen, consisting primarily of interest expense of 1.6B yen on long-term loans of 188.6B yen. Non-operating income of 1.4B yen partially offset this burden. The net non-operating impact was negative 0.2B yen, representing 0.2% of revenue. Interest coverage ratio stood at 10.0x (Operating Income / Interest Expense), indicating adequate but declining debt servicing capacity.
Net income fell 2.7B yen to 10.8B yen with an effective tax rate of 31.1% (Tax Expense 4.9B yen / Profit Before Tax 15.8B yen). The gap between ordinary and net income of 5.0B yen was attributable to normal tax expenses without material extraordinary items. Net margin compressed to 8.4% from 11.5% in the prior period. This represents a revenue-up/profit-down pattern driven by operating deleverage and fixed financial costs.
The Ishinkan segment generated revenue of 127.4B yen with operating income of 16.1B yen, representing an operating margin of 12.6%. This core business accounts for 98.5% of total revenue, establishing it as the dominant revenue driver. Segment margin declined 4.5 percentage points from an implied 17.1% in the prior period (20.0B yen operating profit on 117.0B yen revenue), indicating significant margin pressure in the primary business line. The Comprehensive Medical Support segment recorded revenue of 2.0B yen with an operating loss of 0.1B yen, yielding a negative margin of -5.0%. This segment remains in the development phase with minimal revenue contribution (1.5% of total) and negative profitability. The 17.6 percentage point margin differential between segments reflects the mature, profitable nature of Ishinkan versus the early-stage investment phase of Comprehensive Medical Support. Cross-segment internal transactions were minimal at 2M yen, indicating operationally distinct business units.
[Profitability] Operating margin 12.3% contracted from 17.1% YoY (implied from Operating Income decline of -4.1B yen on revenue base of 117.7B yen), representing deterioration of 4.8 percentage points. Net profit margin 8.4% declined from 11.5% YoY. ROE of 2.9% is substantially below historical performance levels, reflecting both lower net income and increased equity base. Gross profit margin held at 28.7%, indicating pricing power and cost of sales discipline were maintained. [Cash Quality] Cash and deposits 91.6B yen decreased from 108.3B yen YoY, representing a decline of 15.4%. Short-term debt coverage stands at 1.23x (Cash 91.6B yen / Short-term Loans 74.4B yen), providing adequate but not abundant liquidity. The decline in cash position warrants monitoring given elongated receivables cycles. [Investment Efficiency] Asset turnover 0.155 (annualized revenue 517.6B yen / Total Assets 833.5B yen) remains low, reflecting the capital-intensive nature of the business with property, plant and equipment representing 69.6% of total assets. Days Sales Outstanding of 271 days indicates extended collection periods requiring working capital management attention. Cash Conversion Cycle of 257 days is elevated, suggesting operational inefficiency in converting sales to cash. [Financial Health] Equity ratio 44.2% improved marginally from 43.0% YoY, maintaining moderate financial stability. Current ratio 109.7% (Current Assets 204.2B yen / Current Liabilities 186.2B yen) indicates limited short-term liquidity cushion. Debt-to-equity ratio 1.26x (Interest-bearing Debt 263.0B yen / Total Equity 368.3B yen) reflects meaningful leverage, with debt-to-capital at 41.7%.
Cash and deposits decreased 16.7B yen YoY to 91.6B yen, indicating net cash outflow during the period despite profitable operations. Operating profit of 16.0B yen suggests positive operational cash generation, though the magnitude of cash conversion cannot be confirmed without operating cash flow disclosure. Working capital movements show trade receivables increased to 95.9B yen, implying extended customer payment terms consistent with the 271-day DSO metric. Inventories rose 83% to 0.6B yen, though absolute amounts remain immaterial. Trade payables increased 163% to 3.9B yen, suggesting supplier credit utilization increased, providing modest working capital financing. The decline in cash position alongside increased receivables and reduced payables suggests cash was deployed into operational assets and potentially debt service. Interest-bearing debt comprises long-term loans of 188.6B yen and short-term borrowings of 74.4B yen, with the cash position covering 34.8% of total debt. Liquidity assessment indicates adequate near-term solvency with cash covering 1.23x short-term obligations, though elongated receivables cycles create reinvestment friction and potential collection risk exposure.
Ordinary income of 15.8B yen versus operating income of 16.0B yen indicates a net non-operating loss of approximately 0.2B yen. Non-operating expenses of 1.6B yen consist primarily of interest expense on long-term debt, representing a recurring fixed cost burden of 1.2% of revenue. Non-operating income of 1.4B yen partially offsets this burden, though specific components are not detailed in the available data. The non-operating net impact represents 0.2% of revenue, a relatively modest influence on reported earnings. Comprehensive income of 10.8B yen matches net income attributed to owners of parent, with minimal adjustments from remeasurements of defined benefit plans, indicating clean earnings without material other comprehensive income effects. The convergence of operating, ordinary, and net income trends suggests earnings are driven by core operations with limited distortion from extraordinary items. However, the absence of operating cash flow data prevents confirmation of cash earnings quality. The extended Days Sales Outstanding of 271 days raises questions about revenue recognition timing and collectability, creating potential accruals risk. Interest coverage of 10.0x provides adequate cushion but has likely declined from prior periods given operating income reduction. Overall earnings quality assessment is neutral, supported by the absence of extraordinary items but tempered by working capital concerns and unavailable operating cash flow metrics to validate profit-to-cash conversion.
Full-year guidance anticipates revenue of 517.0B yen (YoY +5.1%), operating income of 38.0B yen (YoY -38.3%), and ordinary income of 33.0B yen (YoY -48.0%). Q1 progress rates stand at 25.0% for revenue (129.4B yen / 517.0B yen), 42.1% for operating income (16.0B yen / 38.0B yen), and 47.9% for ordinary income (15.8B yen / 33.0B yen). Operating income progress is 17.1 percentage points ahead of the standard 25% quarterly benchmark, while ordinary income is 22.9 percentage points ahead, indicating front-loaded profit realization or conservative full-year guidance. The company did not revise forecasts during the quarter, maintaining original projections despite Q1 results exceeding proportional quarterly targets on profit metrics. Full-year operating margin guidance implies 7.4% (38.0B yen / 517.0B yen), representing substantial deterioration from the prior year's 12.6% (implied from operating income trends), and below Q1's actual 12.3%. This suggests management anticipates continued margin compression through fiscal year-end, potentially from ongoing facility expansion costs and operational investments. The conservative profit guidance relative to Q1 performance may reflect seasonal patterns, planned investment timing, or prudent outlook given current margin pressures.
Annual dividend is forecasted at 0.00 yen per share according to guidance data, though historical practice indicates a year-end dividend of 4.00 yen based on past patterns. Using the 4.00 yen assumption against Q1 annualized EPS of 44.36 yen (11.09 yen x 4), the implied payout ratio would be 9.0%. However, full-year EPS forecast of 21.53 yen yields a payout ratio of 18.6% if a 4.00 yen dividend is maintained. Given net income guidance of 21.0B yen and 97,531 thousand average shares outstanding, total annual dividends would represent approximately 3.9B yen, resulting in a payout ratio of 18.6% relative to projected earnings. The discrepancy between 0.00 yen stated dividend forecast and historical patterns requires clarification. If no dividend is declared as stated, payout ratio would be 0%, representing a significant policy shift. No share buyback activities are disclosed in the current period data. Without confirmed dividend commitment, total shareholder return assessment is inconclusive, though the balance sheet equity of 368.3B yen and projected net income suggest financial capacity for modest distributions if policy were maintained.
Extended receivables cycle of 271 days creates liquidity risk and potential credit loss exposure. The healthcare services sector typically operates on government and institutional payment systems with structured but lengthy reimbursement schedules. If customer payment patterns deteriorate further or concentration in slow-paying customers increases, working capital demands could strain liquidity despite current 1.23x short-term debt coverage. Mitigation requires enhanced collection processes and customer diversification. Quantified impact: every 30-day increase in DSO consumes approximately 10.6B yen of additional working capital (monthly revenue of 10.6B yen).
Interest rate exposure on 263.0B yen of interest-bearing debt presents earnings sensitivity. Current interest expense of 1.6B yen quarterly (6.4B yen annualized) implies an effective rate of approximately 2.4%. A 100 basis point increase in borrowing costs would elevate annual interest expense by 2.6B yen, reducing pre-tax income by 7.9% relative to current 33.0B yen ordinary income guidance. Given the rising rate environment and debt refinancing requirements on long-term loans of 188.6B yen, interest cost escalation represents material earnings risk absent revenue acceleration or margin recovery.
Operating margin compression from 17.1% to 12.3% reflects structural cost pressures that may persist. SG&A growth of 24.1% substantially exceeded revenue growth of 9.9%, driven by expansion investments and administrative infrastructure buildout. If margin deterioration continues, full-year operating margin of 7.4% implied by guidance could pressure ROE below current 2.9% and threaten dividend capacity. Risk is elevated given the operating leverage in the business model, where fixed facility costs and administrative overhead create inflexibility. Mitigation requires revenue acceleration, facility utilization improvement, or cost restructuring.
[Industry Position] (Reference - Proprietary Analysis) The company operates in a specialized healthcare services sector with characteristics overlapping IT and telecom infrastructure due to medical facility management systems. Profitability metrics show mixed positioning relative to industry standards. Operating margin of 12.3% exceeds the industry median of 5.3% (IQR: 3.0%-26.3%, n=3, 2025-Q1), indicating above-median operational efficiency despite recent compression. Net profit margin of 8.4% substantially exceeds the industry median of 0.6% (IQR: 0.5%-16.6%), ranking in the upper quartile of profitability. However, ROE of 2.9% aligns closely with industry median of 0.2% (IQR: 0.1%-2.3%), reflecting the capital-intensive nature and operational challenges common across the sector. Return on Invested Capital of 2.0% (referenced from analysis) approximates industry median of 0.01 (IQR: 0.01-0.59), indicating comparable capital efficiency challenges. Financial Health metrics show divergence from peers. Equity ratio of 44.2% significantly underperforms the industry median of 68.9% (IQR: 64.1%-79.9%), indicating higher leverage and financial risk relative to typical sector capital structures. Asset turnover of 0.155 falls below industry median of 0.18 (IQR: 0.15-0.19), though within the lower bound of typical performance, consistent with asset-intensive business models. Revenue growth of 9.9% significantly underperforms industry median of 25.5% (IQR: 20.9%-26.2%), suggesting market share challenges or maturity in core business lines relative to faster-growing peers. The Rule of 40 metric (revenue growth + operating margin = 22.2%) substantially underperforms industry median of 0.31 (31%), indicating suboptimal balance between growth and profitability. Overall, the company demonstrates superior profitability margins but faces capital efficiency and growth velocity challenges relative to industry benchmarks, with elevated leverage creating financial flexibility constraints. (Industry: Healthcare Services / IT Infrastructure, n=3 comparison companies, Period: 2025-Q1, Source: Proprietary analysis)
Revenue durability evidenced by 9.9% YoY growth and diversified segment structure with Ishinkan core business contributing stable cash generation. The healthcare services sector benefits from demographic tailwinds and regulatory support in Japan, providing long-term demand visibility. However, growth velocity of 9.9% trails industry median of 25.5%, suggesting market share challenges or business model maturity requiring strategic renewal initiatives.
Capital efficiency deterioration represents the primary structural concern, with ROIC of 2.0% and asset turnover of 0.155 indicating suboptimal returns on deployed capital. Property, plant and equipment of 579.9B yen (69.6% of total assets) creates operational inflexibility and demands sustained utilization improvements. Combined with 271-day DSO and 257-day cash conversion cycle, working capital intensity compounds capital efficiency challenges. Sustained margin compression from 17.1% to 12.3% operating margin, with full-year guidance implying further deterioration to 7.4%, indicates structural profitability pressure. SG&A growth exceeding revenue growth by 14.2 percentage points suggests operational deleverage requiring cost discipline or revenue acceleration to restore historical profitability levels.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.